Emerging non-antibody‒drug conjugates (non-ADCs) therapeutics of toxins for cancer treatment
The non-selective cytotoxicity of toxins limits the clinical relevance of the toxins. In recent years, toxins have been widely used as warheads for antibody‒drug conjugates (ADCs) due to their efficient killing activity against various cancer cells. Although ADCs confer certain targeting properties...
Saved in:
Main Authors: | Xiaolan Xu (Author), Jiaming Zhang (Author), Tao Wang (Author), Jing Li (Author), Yukang Rong (Author), Yanfang Wang (Author), Chenxia Bai (Author), Qing Yan (Author), Xiaohua Ran (Author), Yingli Wang (Author), Tianhong Zhang (Author), Jin Sun (Author), Qikun Jiang (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2024-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Advances in the study of marketed antibody-drug Conjugates (ADCs) for the treatment of breast cancer
by: Yan Liang, et al.
Published: (2024) -
New antibody-drug conjugates (ADCs) in breast cancer-an overview of ADCs recently approved and in later stages of development
by: Kira-Lee Koster, et al.
Published: (2022) -
Antibody-drug conjugates (ADCs) may be a big breakthrough in gynecologic cancer treatment (I)
by: Peng-Hui Wang, et al.
Published: (2024) -
Antibody-drug conjugates (ADCs) may be a big breakthrough in gynecologic cancer treatment (II): Anti-HER2/neu
by: Peng-Hui Wang, et al.
Published: (2024) -
Impact of Endocytosis Mechanisms for the Receptors Targeted by the Currently Approved Antibody-Drug Conjugates (ADCs)-A Necessity for Future ADC Research and Development
by: Manar Hammood, et al.
Published: (2021)